Skip to main content
. 2024 Feb 24;8(7):1715–1724. doi: 10.1182/bloodadvances.2023012044

Table 2.

Median platelet count by use of concomitant ITP medication in the LTE

Observed platelet count, median, ×109/L Rilzabrutinib monotherapy
(n = 5)
Rilzabrutinib + concomitant ITP medication
(n = 11)
Main treatment period, baseline 21 18
At LTE entry 68 156
At LTE 3 mo 90 94
At LTE 6 mo 73 66